Section 1. Introduction
The second sentence in paragraph 3, which currently reads "The full approval requires additional data on the drugs mechanism of action and long-term efficacy and safety [7, 9] ." Should read: "The full approval required additional data [7, 9] from a 2-year carcinogenicity study in rats [8] . This study has been completed and data were submitted to the China CDE in January 2020."
Section 2.1. Pharmacodynamics
The first sentence, which currently reads: "Sodium oligomannate is produced by depolymerizing propylene glycol alginate sodium sulfate followed by oxidation, leaving carboxyl group at the reduced end [11] ." Should read: "Sodium oligomannate is produced by depolymerizing alginate and subsequent oxidation to oligosaccharides [11] ."
The last sentence of paragraph 3, which currently reads: "In the phase II trial, sodium oligomannate treatment was associated with an increase in Aβ 1-42 levels in the cerebrospinal fluid (CSF), suggesting clearance of amyloid from the brain into the CSF [13] ." Should read "In a small (n = 13) phase IIa pilot study, sodium oligomannate treatment was associated with an increase in Aβ 1-42 levels in the cerebrospinal fluid (CSF), suggesting clearance of amyloid from the brain into the CSF [13] ."
Section 2.2 Pharmacokinetics
The second sentence of the first paragraph: the units for AUC∞ should be ng·h/mL.
Section 2.3 Therapeutic Trials.
In the first paragraph, third sentence, which currently reads: "In the full analysis set (n = 678), the primary…" Should read: "In patients who completed the study (n = 678), the primary…"
Features and properties of sodium oligomannate table
The mechanism of action line, which currently reads: "Amino acid modulators; Amyloid beta-protein inhibitors; Microbiome modulators" Should read: "Neuroinflammation modulators; Amyloid beta-protein inhibitors; Microbiome modulators"
The chemical name, which currently reads: "Oligo-B-1 → 4-d-mannuronic acid sodium dibasic acid" Should read: "Sodium oligo-β-1 → 4-d-mannuronic acid-O-dicarboxylic acid"
The original article can be found online at https ://doi.org/10.1007/ s4026 5-020-01268 -1.
Key milestone figure.
This has been amended to indicate that Phase 1 trials were initiated in 2007 and that Phase 1 trials initiated in 2016 included a higher dose.
The original article has been corrected. 
